For your skin
Fades stubborn dark patches like melasma and deep marks left behind by acne or hormonal shifts. The one to reach for when other brighteners haven't worked.
Want the science? Keep reading ↓Mechanism of action
Plasmin inhibitor that interrupts the UV-triggered melanogenesis pathway in keratinocytes.
Why we tier this strong
10 cited papers across 6 countries. Multiple positive efficacy results plus regulatory backing. Our catalog highlights 10 cited papers as direct references, a curated sample from the broader body of published research that earns Tranexamic Acid its Strong tier (15+ studies including multiple RCTs or a large longitudinal cohort). See our methodology for how we evaluate evidence.
Layering matrix
Read the research
Compare with
Cited research
Liang Y et al., Comparative efficacy and safety of tranexamic acid for melasma by different administration methods: A systematic review and network meta-analysis, Journal of Cosmetic Dermatology 2024 — oral TXA + topical agents most effective delivery route
Tranexamic Acid Ameliorates Skin Hyperpigmentation by Downregulating Endothelin-1 Expression in Dermal Microvascular Endothelial Cells, Annals of Dermatology 2024;36(3):151-162 — mechanism study showing oral TXA suppresses endothelin-1 in vascular endothelial cells
Calacattawi R, Alshahrani M, Aleid M et al., Tranexamic acid as a therapeutic option for melasma management: a meta-analysis and systematic review of randomized controlled trials, Journal of Dermatological Treatment 2024;35(1):2361106 — pooled RCT evidence that tranexamic acid significantly reduces melasma severity via plasmin-inhibition of UV-triggered melanogenesis
Ding Y et al. Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment. Pigment Cell Melanoma Res. 2023;36(6):460-473. doi:10.1111/pcmr.13108 — Review of Riehl's melanosis that specifically identifies oral tranexamic acid among therapies showing improved effectiveness.
Feng X et al., Efficacy and safety of tranexamic acid in the treatment of adult melasma: An updated meta-analysis of randomized controlled trials, Journal of Clinical Pharmacy and Therapeutics 2021 — oral TXA is effective and safe for melasma, especially as adjuvant
Nautiyal A, Wairkar S. Management of hyperpigmentation: Current treatments and emerging therapies. Pigment Cell Melanoma Res. 2021;34(6):1000-1014. doi:10.1111/pcmr.12986 — Comprehensive review identifying oral tranexamic acid as a first-line oral therapeutic agent for hyperpigmentation management.
Anwar AI et al., Randomized control trial outcomes of tranexamic acid combination serum as a depigmenting agent, Dermatologic Therapy 2019
Tranexamic Acid Diminishes Laser-Induced Melanogenesis, Annals of Dermatology 2015;27(3):250-256 — TXA reduces melanin production and tyrosinase activity in melanocytes; candidate for post-inflammatory hyperpigmentation
Na JI et al., Effect of tranexamic acid on melasma: a clinical trial with histological evaluation, Journal of the European Academy of Dermatology and Venereology 2013 — topical TXA reduced melasma severity with corresponding histological pigment reduction
Maeda K, Naganuma M, Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation, Journal of Photochemistry and Photobiology B 1998;47(2-3):136-41
Sources: 10 clinical journals and regulatory databases across the US, EU, Korea, Japan, and China. Every entry points to a specific document. See methodology for the full list and what each outcome label means.